Gilead Sciences GILD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.02B-7.4% | $2.18B-28.5% | $3.05B+55.7% | $1.96B+49.0% | $1.32B-26.2% | ||
| $218M-5.2% | $230M0.0% | $230M+2.2% | $225M+7.7% | $209M-5.9% | ||
| $179M— | —— | $659M+470% | -$178M+10.6% | -$199M+47.5% | ||
| -$134M— | —— | $333M+14.0% | $292M+470% | -$79M-9.7% | ||
| $52M-57.7% | $123M-76.1% | $515M+194% | $175M-21.5% | $223M-1.3% | ||
| -$67M+29.5% | -$95M— | —— | -$162M-54.3% | -$105M— | ||
| -$702M— | —— | $811M+589% | -$166M+32.0% | -$244M-180% | ||
| -$29M+78.4% | -$134M-9.8% | -$122M+90.6% | -$1.3B-136% | -$552M— | ||
| $2.54B-23.5% | $3.33B-19.0% | $4.11B+397% | $827M-52.9% | $1.76B-40.9% | ||
| $117M-42.9% | $205M+39.5% | $147M+37.4% | $107M+2.9% | $104M-29.3% | ||
| $109M-82.1% | $609M+265% | $167M+695% | $21M-92.3% | $273M+264% | ||
| $525M-62.0% | $1.38B+412% | $270M-86.5% | $2B— | $0— | ||
| $1.77B+196% | -$1.84B-330% | -$427M+79.8% | -$2.12B-410% | -$415M-84.4% | ||
| $1.04B+4.6% | $994M-1.1% | $1.01B+1.1% | $994M-1.6% | $1.01B+3.8% | ||
| $419M+82.2% | $230M-47.1% | $435M-17.5% | $527M-27.8% | $730M+109% | ||
| $166M+419% | $32M-67.0% | $97M+259% | $27M-89.3% | $252M+45.7% | ||
| -$4.24B-236% | -$1.26B+15.2% | -$1.49B+5.0% | -$1.57B+54.3% | -$3.43B— | ||
| -$11M-320% | $5M— | $0-100% | $73M+284% | $19M+135% | ||
| $65M— | —— | —— | -$2.78B-34.8% | -$2.07B-142% | ||
| $596M-0.2% | $597M+0.2% | $596M-0.3% | $598M-0.2% | $599M+0.2% | ||
| $93M+3.3% | $90M0.0% | $90M-3.2% | $93M-4.1% | $97M+2.1% | ||
| -$5M-114% | $36M-90.2% | $368M+554% | -$81M-575% | -$12M-108% | ||
| -$183M+31.5% | -$267M-200% | -$89M-170% | -$33M+63.7% | -$91M-54.2% | ||
| $107M-80.1% | $539M+217% | $170M+179% | $61M-75.9% | $253M— | ||
| $17M+255% | -$11M— | —— | —— | $23M+166% | ||
| $19M+35.7% | $14M-82.9% | $82M+290% | $21M+31.3% | $16M-59.0% | ||
| $36M+56.5% | $23M+35.3% | $17M+13.3% | $15M— | $0— | ||
| $2.52B+641% | $340M+55.3% | $219M-25.8% | $295M— | $0— | ||
| -$179M-184% | -$63M+54.0% | -$137M-114% | -$64M+63.6% | -$176M-274% | ||
| $2.77B+34,475% | $8M-11.1% | $9M0.0% | $9M-99.5% | $1.76B+25,071% | ||
| $2.43B-22.3% | $3.12B-21.2% | $3.96B+450% | $720M-56.4% | $1.65B-41.5% | ||
| $2.43B-22.3% | $3.12B-21.2% | $3.96B+450% | $720M-56.4% | $1.65B-41.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gilead Sciences generate?
- Gilead Sciences (GILD) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Gilead Sciences's free cash flow?
- After $576.0M of capital expenditures, Gilead Sciences's free cash flow was $10.2B over the trailing twelve months, up 3.9% year over year.
- Where does Gilead Sciences's cash flow data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
